Criteria
| Eligible Active Ingredient: | Levocetirizine tablet. As an oral solid preparation containing not more than 5mg |
| With Effective From: | 1-Jul-2012 |
| Indication Permitted: | For the symptomatic treatment of allergic rhinitis and chronic idiopathic urticaria. |
| Maximum Daily Dose: | 5mg |
| Maximum Supply per Transaction: | 10 tablets |
| Minimum Age of User: | 12 years |
| Patient Information Leaflet from HSA/PSS: | Download PIL (Link to HSA website) |
Mechanism of Action of Levocetirizine tablet
Levocetirizine, the active enantiomer of cetirizine, is an anti-histamine; its principal effects are mediated via selective inhibition of H1 receptors. The antihistaminic activity of levocetirizine has been documented in a variety of animal and human models. In vitro binding studies revealed that levocetirizine has an affinity for the human H1-receptor 2-fold higher than that of cetirizine (Ki = 3 nmol/L vs. 6 nmol/L, respectively). This increased affinity has unknown clinical relevance.
Additional Information of Levocetirizine tablet
| Pharmacology Class: | Antihistamines For Systemic Use |
| Therapeutic Class: | Antihistamines For Systemic Use |
| Chemical Class: | Piperazine Derivatives |
| Synonyms: | 2-(2-{4-[(R)-(4-chlorophenyl)(phenyl)methyl]piperazin-1-yl}ethoxy)acetic acid |
Show All HSA-registered therapeutic products granted exemption to supply without prescription
References
HSA-Registered Products Containing Levocetirizine tablet As an oral solid preparation containing not more than 5mg
wpDataTable with provided ID not found!
This list is not exhaustive. HSA collaborates with Pharmaceurical Society of Singapore (PSS) to review the appropriate use of therapeutic products in the community from time to time. Hence, HSA may enable the supply of a Prescription Only Medicine (POM) by pharmacists without a prescription, upon review that the product can be used in a safe and effective manner under the supervision of a pharmacist. This can be effected through legislative mechanisms in the absence of an application made by the product registrant to reclassify the therapeutic product, subject to to conditions including indication, strength, maximum daily dose, maximum supply quantity, and age restriction.